New Delhi: In a recent study done by the Indian Council of Medical Research (ICMR) found that the indigenously developed Covaxin is more effective against Delta (B.1.617.2) and Beta (B.1.351) variants of SARS-CoV-2, that causes coronavirus.
The above-mentioned research – ‘Neutralisation against B.1.351 and B.1.617.2 with sera of Covid-19 recovered cases and vaccinees of BBV152’ – has not been peer-reviewed yet.
According to the research, which was done to study the neutralisation potential of the COVID-19 vaccine Covaxin, they discovered a threefold and 2.7-fold reduction in neutralisation titers against the Delta and Beta variants of COVID-19 respectively. The neutralising titre points out to the level of antibodies created.
“The finding of the study demonstrated a reduction in neutralization titers with sera of COVID-19 recovered cases (3.3-fold and 4.6-fold) and BBV152 vaccinees (3.0 and 2.7 fold) against B.1.351 and B.1.617.2 respectively,” the study said.
Researchers at the Indian Council of Medical Research – National Institute of Virology (NIV) assessed the neutralisation possibility of sera collected from 20 recovered coronavirus patients and 17 people, who had received the second jab of the Covaxin 28 days before the study.
Furthermore, the scientists concluded that in spite of a reduction in neutralisation titer, the whole-virion inactivated vaccine showed an effective response against the two above-mentioned variants of COVID-19.
Covaxin is developed by Hyderabad-based vaccine maker Bharat Biotech, in association with ICMR. It is also one of the three COVID-19 vaccines presently being administered in India.
Serum Institute of India (SII)’s Covishield and Russia’s Sputnik V are the two other vaccines which are being used for the coronavirus inoculation drive in India.